Clinical Trials Logo

CLL/SLL clinical trials

View clinical trials related to CLL/SLL.

Filter by:

NCT ID: NCT04523428 Recruiting - CLL/SLL Clinical Trials

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Start date: December 23, 2020
Phase: Phase 2
Study type: Interventional

Fixed-duration regimens containing combinations of venetoclax with CD20 targeting agents are expected to soon become standard practice in first-line patients with chronic lymfocytic leukemia (CLL). The advantage of a fixed duration venetoclax combination as part of first-line treatment is the potential to retreat with venetoclax in patients who develop relapsed disease after a treatment free period. However, efficacy of venetoclax retreatment following a fixed duration venetoclax combination is still hypothetical as clinical data are lacking. Thus, there is an urgent need for data proving efficacy of venetoclax combinations following venetoclax treatment cessation. Testing of a novel venetoclax-containing regimen for relapsed CLL without the repeat of anti-CD20 monoclonal antibody (mAb) is a rational approach.

NCT ID: NCT04215809 Recruiting - CLL/SLL Clinical Trials

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Start date: March 2, 2020
Phase: Phase 1
Study type: Interventional

Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.